Increasing Tysabri dosing interval may cut PML risk

A board to discuss the newly-released drug Tysabri, (formerly known as Antegren) as a treatment for Multiple Sclerosis

Increasing Tysabri dosing interval may cut PML risk

Postby MSUK » Thu Apr 23, 2015 7:11 am

Freedom from relapse was maintained in multiple sclerosis patients on Tysabri who received the infusion drug less frequently than the recommended 4-week interval, with lower risk of progressive multifocal leukoencephalopathy (PML), preliminary results from an ongoing analysis have indicated...... Read More - http://www.ms-uk.org/tysabri
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2876
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Re: Increasing Tysabri dosing interval may cut PML risk

Postby NHE » Fri Apr 24, 2015 11:56 pm

Prior to any flag waving, please note that this is not a randomized double blind controlled trial...
Weinshenker commented that selection of patients for extended dosing, which was not random, might have involved "biases against committing more aggressive MS patients on the extended interval program, which might reduce the ability of the investigators to detect reduction in efficacy."
User avatar
NHE
Volunteer Moderator
 
Posts: 4557
Joined: Sat Nov 20, 2004 3:00 pm


Return to Tysabri (Antegren or Natalizumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service